10月8日，百济神州盘中下跌5.1%，报345.445美元/股，成交额2730.42万美元。
消息面上，公司董事、科学顾问委员会主席王晓东于9月下旬两次集中减持，累计套现超2468万美元，其中10月1日披露的一笔交易涉及3.10万份ADS，加权均价约364.79美元，套现约1131.86万美元。创始股东连续减持对短期市场情绪形成压制。
尽管公司中期业绩表现强劲，上半年净利润同比增长385.8%至4.64亿美元，且近期在港股生物医药板块中获得资金关注，但高管减持行为仍构成直接影响本次股价异动的关键事件。
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物，主要产品为抗肿瘤类药物。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.